
    
      PRIMARY OBJECTIVES:

      I. To evaluate the response rate in patients receiving SAHA for stage IV breast cancer.

      SECONDARY OBJECTIVES:

      I. Time to progression. II. Overall survival. III. Toxicity profile. IV. Assessment of
      potential biological correlates.

      OUTLINE: This is a multicenter study.

      Patients receive oral suberoylanilide hydroxamic acid twice daily on days 1-14. Courses
      repeat every 21 days in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed for 8 weeks.
    
  